2026-05-26T09:31:16-05:00 2025-12-31 873778434 GIL & SCHONIG CPAS LLP 1 HUNTINGTON QUADRANGLE SUITE 4S01 MELVILLE NY 11747 990 2025-01-01 251922851 TISCH MULTIPLE SCLEROSIS RESEARCH CENTER OF NEW YORK INC TISC 6465573900 521 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 AMANDA B OPPENHEIMER CHIEF OPERATING OFFICER 6465573900 2026-05-26 1 MICHAEL W SCHONIG P01469580 5167672760 2025 2025-03-06 01:10:19Z AMANDA B OPPENHEIMER 521 W 57TH ST NEW YORK NY 10019 10112779 0 X WWW.TISCHMS.ORG X 2005 NY SEE SCHEDULE O. 31 30 38 0 0 0 5576393 5829026 247000 31939 -16378 -6780 4565248 3657760 10372263 9511945 0 0 0 0 3585538 3273559 0 0 747765 7102504 6147484 10688042 9421043 -315779 90902 29507214 27670515 14293531 12361206 15213683 15309309 X THE PURPOSE OF TISCH MULTIPLE SCLEROSIS RESEARCH CENTER OF NY, INC. IS TO CONDUCT MEDICAL RESEARCH DIRECTED TOWARD FINDING THE CAUSE AND EVENTUAL CURE FOR MULTIPLE SCLEROSIS. 0 0 7540138 9518725 SEE SCHEDULE O. 6672 SEE SCHEDULE O. 7546810 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 1 0 1 1 0 0 0 0 0 0 0 0 1 36 0 38 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 31 30 1 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY NJ CT MA PA FL CA WA X X X AMANDA OPPENHEIMER 6465573900 CPA 521 W 57TH ST 4TH FLOOR NEW YORK NY 10019 PHILIP WEISBERG CHAIR 5.00 X X 0 0 0 PHILIP R PELLER AUDIT COMMITTEE CHAIR 2.00 X 0 0 0 BERNADETTE MARIANI NOMINATING COMMITTEE CHAIR 2.00 X 0 0 0 WILLIAM M DRUMMY JR DEVELOPMENT COMMITTEE CHAIR 2.00 X 0 0 0 SAUD A SADIQ MD DIRECTOR/CHIEF RESEARCH SCIENTIST 15.00 X X 0 0 0 LEE J SEIDLER CHAIRMAN EMERITUS 0.50 X 0 0 0 AMANDA B OPPENHEIMER CHIEF OPERATING OFFICER 40.00 X 177186 0 14734 CLIFFORD EISLER TREASURER 2.00 X X 0 0 0 SHARYL REISMAN SECRETARY 2.00 X X 0 0 0 TALENE KELLY DIRECTOR OF DEVELOPMENT 40.00 X 145206 0 5589 JAMES CONNELL DIRECTOR 0.50 X 0 0 0 MANNY SCHNAIDMAN DIRECTOR 0.50 X 0 0 0 ALAN TISCH DIRECTOR 0.50 X 0 0 0 THOMAS R MAYER DIRECTOR 0.50 X 0 0 0 MUSA MAYER DIRECTOR 0.50 X 0 0 0 PAUL PURCELL DIRECTOR 0.50 X 0 0 0 PHILIP J PURCELL DIRECTOR 0.50 X 0 0 0 ALLA WEISBERG DIRECTOR 0.50 X 0 0 0 DANIEL TISCH DIRECTOR 0.50 X 0 0 0 BONNIE TISCH DIRECTOR 0.50 X 0 0 0 RICHARD SCHWARTZ DIRECTOR 0.50 X 0 0 0 GRETA RUBIN SCHWARTZ DIRECTOR 0.50 X 0 0 0 MONIKA PAREKH DIRECTOR 0.50 X 0 0 0 DEVEN PAREKH DIRECTOR 0.50 X 0 0 0 ELIZABETH MASLOW MONTESANO DIRECTOR 0.50 X 0 0 0 JAMES MARIANI DIRECTOR 0.50 X 0 0 0 PAUL LATTANZIO DIRECTOR 0.50 X 0 0 0 CHARLES THOELE DIRECTOR 0.50 X 0 0 0 BRADLEY H FRIEDRICH DIRECTOR 0.50 X 0 0 0 BONNIE EISLER DIRECTOR 0.50 X 0 0 0 CYNTHIA D BRODSKY DIRECTOR 0.50 X 0 0 0 ENKE BASHLLARI PHD DIRECTOR 0.50 X 0 0 0 HILLARY MANDEL DIRECTOR 0.50 X 0 0 0 VIOLAINE HARRIS SENIOR RESEARCH SCIENTIST 40.00 X 255540 0 16563 JERRY LIN SENIOR STAFF ASSOCIATE 40.00 X 135882 0 10951 JAMIE WONG RESEARCH SCIENTIST 40.00 X 148790 0 11887 862604 0 59724 5 1 1 0 CONROY CONSTRUCTION INC 135 E WASHINGTON AVE PEARL RIVER NY 10965 GENERAL CONTRACTOR 582444 MISPRO BIOTECH SERVICES CORP 11-2901 RACHEL STREET EAST MONTREAL QUEBEC CA H1W 4A4 VIVARIUM OPERATIONS 167873 CIPRIANI 110 EAST 42ND S NEW YORK NY 10017 VENUE 161650 WHITE WINGS CONSULTING LLC 110 WEST 34TH STREET SUITE 1106 NEW YORK NY 10001 INFORMATION TECHNOLOGY 113366 4 5829026 265851 5829026 GENE THERAPY PROGRAM 621500 31939 31939 0 0 31939 226 226 258845 265851 -7006 -7006 -7006 3992743 334983 3657760 3657760 9511945 24933 0 3657986 2352038 1745526 406207 200305 680750 493907 129072 57771 240771 172919 50199 17653 37812 21329 16483 33736 33736 210311 33606 85534 91171 2814982 2250997 282805 281180 29539 29539 210 210 1496332 1346698 74817 74817 118530 72736 37203 8591 LAB SUPPLIES, SERVICES, 1145339 1145339 0 0 EQUIPMENT REPAIRS AND M 254618 234214 10202 10202 FUNDRAISING EXPENSE 6075 0 0 6075 9421043 7546810 1126468 747765 3040370 3520301 136795 0 0 31939 663966 621831 26453245 13726584 12603060 12726661 13063023 10769783 29507214 27670515 323790 653553 22475 13969741 11685178 14293531 12361206 X 15213683 15182794 0 126515 15213683 15309309 29507214 27670515 X 90902 4724 0 X X 0 1 X 1 0 X 8963171 6839857 6778214 5576393 5829026 33986661 2768420 3613926 4139547 4812248 3689699 19023840 0 0 0 0 0 -4875 -14871 -1895 -8044 -7006 -36691 11726716 10438912 10915866 10380597 9511719 52973810 0 0 0 52973810 1227 5924 32253 7994 226 47624 1227 5924 32253 7994 226 47624 0 0 0 0 0 11727943 10444836 10948119 10388591 9511945 53021434 0.99910 0.99910 0.00090 0.00090 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 18504106 8591268 9912838 6955091 4320061 2635030 994048 815255 178793 12726661 RIGHT OF USE ASSET 10736100 SECURITY DEPOSIT 33683 10769783 CURRENT PORTION OF OPERATING LEASE LIABILITY 2394262 OPERATING LEASE LIABILITY 9290916 11685178 X 9886945 375000 375000 9511945 0 9511945 9796044 375000 375000 9421044 0 9421044 PART X, LINE 2: PER ASC 740-10, ALL TAX POSITIONS HAVE BEEN EVALUATED AND HAS BEEN DETERMINED THERE ARE NO UNCERTAIN TAX POSITIONS REQUIRING RECOGNITION OR DISCLOSURES. ANNUAL GALA DINNER 3992743 3992743 334983 3992743 3992743 334983 334983 3657760 0 0 0 0 0 0 0 0 0 AMANDA B OPPENHEIMER CHIEF OPERATING OFFICER 177186 0 0 0 0 0 14734 0 0 0 191920 0 0 0 TALENE KELLY DIRECTOR OF DEVELOPMENT 145206 0 0 0 0 0 5589 0 0 0 150795 0 0 0 VIOLAINE HARRIS SENIOR RESEARCH SCIENTIST 255540 0 0 0 0 0 16563 0 0 0 272103 0 0 0 JERRY LIN SENIOR STAFF ASSOCIATE 135882 0 0 0 0 0 10951 0 0 0 146833 0 0 0 JAMIE WONG RESEARCH SCIENTIST 148790 0 0 0 0 0 11887 0 0 0 160677 0 0 0 INT'L MS MGT PRACTICE DR SADIQ IS 100% SH SHARED COSTS X 100000 22475 0 1 0 22475 INT'L MS MGT PRACTICE OF NY PC DR SADIQ IS 100% SH OF PRACTICE 2885680 RENT, SHARED EXPENSES, CLINICAL SAMPLES AND PROCEDURES 0 X 10 265852 FAIR MARKET VALUE 0 1 1 PART I, LINE 32B: STOCK IS GIFTED TO THE RESEARCH CENTER. THE BENEFACTOR TRANSFERS TITLE TO WELLS FARGO, WHO THEN SELLS THE GIFTED STOCK ON THE OPEN MARKET. FORM 990, PART I, LINE 1 THE PURPOSE OF TISCH MULTIPLE SCLEROSIS RESEARCH CENTER OF NY, INC. IS TO CONDUCT MEDICAL RESEARCH DIRECTED TOWARD FINDING THE CAUSE AND EVENTUAL CURE FOR MULTIPLE SCLEROSIS. FORM 990, PART III, LINE 4A TISCH MS RESEARCH CENTER OF NEW YORK'S (TISCH MSRCNY) MISSION IS TO CONDUCT MEDICAL RESEARCH DIRECTED TOWARD DISCOVERING THE CAUSE OF AND EVENTUAL CURE FOR MULTIPLE SCLEROSIS. THESE RESEARCH INITIATIVES INCLUDE: TO BETTER UNDERSTAND AND TREAT COORDINATION AND BALANCE DIFFICULTIES IN PATIENTS WITH MS. TO CREATE AN EXPERIMENTAL MODEL OF PROGRESSIVE MS THAT WILL ENABLE US TO BETTER UNDERSTAND AND TREAT PATIENTS WITH SECONDARY PROGRESSIVE MS (SPMS) AND PRIMARY PROGRESSIVE MS (PPMS). TO UTILIZE NOVEL CEREBROSPINAL FLUID BASED ANIMAL MODELS TO BETTER UNDERSTAND OTHER NEURODEGENERATIVE DISEASES SUCH AS MS AND ALS. TO DEVELOP ORGANOID MODELS TO BETTER UNDERSTAND THE UNDERPINNINGS OF PROGRESSIVE MS. FINALLY, AND PERHAPS MOST IMPORTANTLY, TO IDENTIFY THE INITIAL TRIGGER(S) THAT CAUSE MS. IN 2025, DRS WONG AND SADIQ PUBLISHED RESULTS FROM A COLLABORATION WITH NEURON23, INC. IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. THE STUDY USED THE PPMS ANIMAL MODEL DEVELOPED AT TISCH MS TO DEMONSTRATE PROOF OF CONCEPT OF A NOVEL MS THERAPEUTIC. IN 2025, TISCH MSRCNY RESEARCHERS WERE INVITED TO PRESENT RESEARCH ABSTRACTS AT THE ANNUAL CONFERENCES OF ACTRIMS (AMERICAS COMMITTEE FOR TREATMENT AND RESEARCH IN MS), THE AMERICAN ADADEMY OF NEUROLOGY AND THE SOCIETY FOR NEUROSCIENCE. FORM 990, PART III, LINE 4B AS AN ACADEMIC FACILITY, THE TISCH MS RESEARCH CENTER PROVIDES EDUCATIONAL AND TRAINING RESOURCES FOR MS RESEARCHERS AND MEDICAL PROFESSIONALS. ONE OF THE MOST IMPORTANT GOALS OF TISCH MSRCNY IS TO PROVIDE RESEARCH OPPORTUNITIES FOR YOUNG SCIENCE GRADUATES THAT ENABLE THEM TO BECOME CAREER SCIENTISTS. SINCE ITS INCEPTION, THEY HAVE TRAINED OVER 100 COLLEGE GRADUATES AS RESEARCH ASSISTANTS (RAS) FOR 2-YEAR ROTATIONS. IN 2025, ALL SECOND YEAR RESEARCH ASSISTANTS, UNDER THE GUIDANCE OF TISCH MSRCNY PRINCIPAL INVESTIGATORS, MATRICULATED TO TOP MEDICAL SCHOOLS AND GRADUATE PROGRAMS. FELLOWSHIPS IN MS RESEARCH ARE ALSO OFFERED TO PHYSICIANS AND SCIENTISTS INTERESTED IN ENTERING OR EXPANDING THEIR WORK IN THIS FIELD. WEEKLY JOURNAL CLUB MEETINGS OR GRAND ROUNDS TAKE PLACE IN OUR CONFERENCE ROOM TO DISCUSS THE LATEST ADVANCEMENTS IN MS RESEARCH AND HOW IT APPLIES TO OUR CURRENT INVESTIGATIONS. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS ARE RELATED AS HUSBAND AND WIFE: THOMAS AND MUSA MAYER CLIFFORD AND BONNIE EISLER RICHARD AND GRETA RUBIN SCHWARTZ JAMES AND BERNADETTE MARIANI DEVEN AND MONIKA PAREKH PHIL AND ALLA WEISBERG DANIEL AND BONNIE TISCH FORM 990, PART VI, SECTION A, LINE 4 CHANGES TO BYLAWS: ARTICLE II, SECTION 2(B) "ENTIRE BOARD" DEFINITION EXPANDED TO EXPLICITLY BE DEFINED AS "THE TOTAL NUMBER OF DIRECTORS ENTITLED TO VOTE WHICH THE CORPORATION WOULD HAVE IF THERE WERE NO VACANCIES, AND INCLUDES "THE TERMS OF ANY DIRECTORS WHOSE TERMS HAVE NOT YET EXPIRED." ARTICLE II, SECTION 3 MEETING SUCCESSION HAS BEEN CLARIFIED. IF BOTH THE CHAIR AND VICE CHAIR(S) ARE ABSENT, A DIRECTOR DESIGNATED BY THE CHAIR WHO IS ON THE EXECUTIVE COMMITTEE PRESIDES (BEFORE DEFAULTING TO A DIRECTOR CHOSEN BY MAJORITY). THE PREVIOUS BYLAWS WENT FROM VICE CHAIR TO MAJORITY-CHOSEN DIRECTOR. ARTICLE II, SECTION 4 REMOVAL OF A DIRECTOR NOW REQUIRES CAUSE. THIS HAS BEEN CHANGED FROM "WITH OR WITHOUT CAUSE" TO "WITH CAUSE" BY MAJORITY OF THE ENTIRE BOARD. ARTICLE II, SECTION 6 VIRTUAL MEETINGS EXPLICITLY AUTHORIZED WITH NEW LANGUAGE: MEETINGS MAY BE HELD "INCLUDING VIRTUALLY." ARTICLE II, SECTION 6 NOTICE METHODS NARROWED. THE PREVIOUS BYLAWS ALLOWED NOTICE ORALLY (1 DAY), OR BY FAX/EMAIL/MAIL (3 DAYS). THE NEW BYLAWS ALLOW ONLY EMAIL, MAIL, OR COURIER, ALL WITH A UNIFORM 3-DAY NOTICE. ORAL, TELEPHONE, AND FAX NOTICE ARE ELIMINATED. ARTICLE II, SECTION 6 "WITHOUT NOTICE" LANGUAGE FOR REGULAR MEETINGS HAS BEEN REMOVED. ARTICLE II, SECTION 8 ADJOURNMENT NOW REQUIRES NOTICE. PREVIOUSLY, AN ADJOURNED MEETING COULD BE MOVED "WITHOUT NOTICE TO ANY DIRECTOR." THE NEW BYLAWS REQUIRE NOTICE FROM DIRECTORS NOT PRESENT AT THE ADJOURNMENT UNLESS ANNOUNCED AT THE MEETING. ARTICLE II, SECTION 9(A) RECUSED DIRECTORS COUNT TOWARD QUORUM. NEW PROVISION: DIRECTORS PRESENT BUT NOT VOTING DUE TO A CONFLICT OF INTEREST OR RELATED-PARTY TRANSACTION ARE STILL "PRESENT" FOR QUORUM PURPOSES AT THE TIME OF THE VOTE. ARTICLE II, SECTION 9(B) THE PREVIOUS BYLAWS ALLOWED REAL PROPERTY TRANSACTIONS NOT REQUIRING BOARD APPROVAL TO BE APPROVED BY A COMMITTEE. NEW LANGUAGE ON THE CHANGED BYLAWS NOW REQUIRES A MAJORITY VOTE OF THE BOARD OR A COMMITTEE FOR ANY SUCH "OTHER" REAL PROPERTY TRANSACTION. ARTICLE II, SECTION 10 ANNUAL REPORT PRESENTER CHANGED. THE PREVIOUS BYLAWS HAD THE BOARD PRESENT THE REPORT, CERTIFIED BY INDEPENDENT ACCOUNTANTS. THE NEW BYLAWS HAVE THE PRESIDENT AND TREASURER PRESENT THE ANNUAL REPORT AND ALLOW VERIFICATION BY THE P&T OR A MAJORITY OF DIRECTORS AS AN ALTERNATIVE TO CERTIFICATION BY INDEPENDENT ACCOUNTANTS. ARTICLE II, SECTION 11(B) TREASURER MAY DELEGATE. ADDED OR THEIR DESIGNATE" TO THE TREASURER'S ANNUAL DONOR-RESTRICTED ASSET REPORTING DUTY. ARTICLE III, SECTION 1 HEIGHTENED THRESHOLD FOR EXECUTIVE COMMITTEE APPOINTMENTS ON LARGE BOARDS. WHEN THE BOARD HAS 30 OR MORE MEMBERS, EXECUTIVE COMMITTEE APPOINTMENTS NOW REQUIRE THREE-QUARTERS OF THE DIRECTORS TO BE PRESENT RATHER THAN A SIMPLE MAJORITY OF THE ENTIRE BOARD. ARTICLE III, SECTION 1 SIGNIFICANTLY EXPANDED LIST OF ACTIONS COMMITTEES CANNOT TAKE. NEW RESTRICTIONS ADDED BEYOND THE ORIGINAL FOUR: (E) ELECTING OR REMOVING OFFICERS AND DIRECTORS, (F) APPROVING MERGERS OR PLANS OF DISSOLUTION, (G) AUTHORIZING SALE/LEASE/DISPOSITION OF ALL OR SUBSTANTIALLY ALL ASSETS, AND (H) APPROVING AMENDMENTS TO THE CERTIFICATE OF INCORPORATION. ARTICLE III, SECTION 2 NON-DIRECTORS MAY SERVE ON COMMITTEES OF THE CORPORATION. NEW LANGUAGE EXPLICITLY PERMITS NON-DIRECTORS TO SERVE ON THESE (NON-BOARD) COMMITTEES. ARTICLE III, SECTION 4 NOMINATING COMMITTEE ROLE CLARIFIED. THE COMMITTEE NOW PRESENTS NOMINEES "FOR THEM [THE BOARD] TO VOTE UPON" RATHER THAN "FOR NOMINATION." ARTICLE IV, SECTION 8 BACKUP PRESIDER WHEN NO VICE CHAIR. IF THERE IS NO VICE CHAIR, A MEMBER OF THE EXECUTIVE COMMITTEE SELECTED BY THE BOARD PRESIDES. ARTICLE IV, SECTION 9 TREASURER'S ROLE REMOVED THE BOND REQUIREMENT ("IF REQUIRED BY THE BOARD OBTAIN A BOND"). ADDED NEW OVERSIGHT RESPONSIBILITIES SUCH AS, ASSISTING THE BOARD WITH FINANCIAL OVERSIGHT AND LEGAL/REGULATORY COMPLIANCE, WORKING "IN CONJUNCTION WITH THE AUDIT COMMITTEE," ENSURING SOUND FINANCIAL PRACTICES AND TIMELY REPORTING, AND A "KEY ROLE" IN BUDGETING, FINANCIAL PLANNING, AND MONITORING FISCAL POLICIES. EXPLICITLY ALLOWS THE TREASURER TO DELEGATE BOOKKEEPING/CUSTODY DUTIES TO STAFF. ARTICLE IV, SECTION 10 NEW PARAGRAPH PERMITS THE SECRETARY TO DELEGATE DUTIES TO STAFF WHILE RETAINING OVERALL RESPONSIBILITY. ARTICLE VII, SECTION 3 ADVANCEMENT OF EXPENSES HAVE BEEN MODIFIED TO INCLUDE TWO NEW CONDITIONS: (1) THE BOARD MUST DETERMINE THE PERSON WAS ACTING IN GOOD FAITH BEFORE ADVANCING EXPENSES, AND (2) THE REPAYMENT OBLIGATION NOW ALSO COVERS SITUATIONS "WHERE INDEMNIFICATION IS GRANTED, TO THE EXTENT THE EXPENSES SO ADVANCED EXCEED THE INDEMNIFICATION TO WHICH HE/SHE IS ENTITLED." ARTICLE VIII, SECTION 2 WHISTLEBLOWER POLICY IS NOW REQUIRED. THE LIST OF POLICIES THE BOARD MUST ADOPT NOW EXPLICITLY INCLUDES A WHISTLEBLOWER POLICY IN ADDITION TO A CONFLICTS OF INTEREST POLICY WHILE ALSO ADDING "AS ARE REQUIRED BY LAW" TO THE POLICIES THE BOARD MUST ADOPT. ARTICLE VIII, SECTION 3 BOOKS AND RECORDS SCOPE HAVE BEEN BROADENED TO NOW REQUIRE MINUTES TO COVER "ANY COMMITTEES OF THE BOARD" RATHER THAN ONLY "ANY STANDING COMMITTEES OF THE BOARD." FORM 990, PART VI, SECTION B, LINE 11B WHEN FORM 990 IS PRESENTED TO THE ORGANIZATION, THE AUDIT COMMITTEE WILL REVIEW AND SEND IT TO THE BOARD FOR COMMENT. IF NONE IS RECEIVED IN 7 DAYS, THE RETURN IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD MEMBERS COMPLETE AN "ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT." FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED USING PUBLICLY AVAILABLE COMPENSATION INFORMATION FROM COMPARABLE RESEARCH ORGANIZATIONS AND UNIVERSITIES, WHICH IS REVIEWED AND APPROVED BY DR. SADIQ. COMPENSATION IS DETERMINED USING PUBLICLY AVAILABLE COMPENSATION INFORMATION FROM COMPARABLE RESEARCH ORGANIZATIONS AND UNIVERSITIES, WHICH IS REVIEWED AND APPROVED BY DR. SADIQ. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S WEBSITE WILL DISPLAY THE FINANCIALS AND FORM 990 FOR PUBLIC VIEWING. IN ADDITION, BOTH THE FINANCIALS AND FORM 990 ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE PROCESS OF OVERSEEING THE AUDIT AND SELECTION OF INDEPENDENT ACCOUNTANT'S HAS NOT BEEN CHANGED FROM PRIOR YEAR. PT XI: GIFTS IN KIND - GOODS AND MATERIALS OTHER: REQUIRED DISCLOSURE OF NON-CASH SECURITIES FROM ANONYMOUS DONORS TOTALING $9,903.